The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Akpinar S., Dogu M. H., ÇELİK S., Ekinci O., Hindilerden I. Y., Dal M. S., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.22, sa.3, ss.169-173, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 3
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.clml.2021.09.010
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.169-173
  • Anahtar Kelimeler: Chronic lymphocytic leukemia, Bruton tyrosine kinase, Ibrutinib, Relapsed/refractory, p53 mutation, CHRONIC LYMPHOCYTIC-LEUKEMIA
  • İstanbul Üniversitesi Adresli: Evet

Özet

We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.